You are here: Industry Insights > Dupixent

News List

Dupixent's on a roll in eczema and asthma, but COPD's a ‘much tougher’ malady fiercepharma
May 09, 2019
Armed with new nods in asthma and adolescent eczema, Regeneron’s Dupixent keeps reeling in new biologics patients.
Dupixent's on a roll in eczema and asthma, but COPD's a ‘much tougher’ malady biospectrumasia
May 09, 2019
According to the World Health Organization, almost 165,000 new cancer cases are diagnosed in Vietnam each year.
AstraZeneca's Fasenra keeps the heat on GSK's Nucala with new phase 2 data fiercepharma
April 10, 2019
AstraZeneca’s Fasenra is already pressuring GlaxoSmithKline's Nucala in severe eosinophilic asthma, and new data could help set up a showdown between the two in another indication.
On a roll, Dupixent marches into teen eczema, nabs fast FDA review in sinusitis fiercepharma
March 13, 2019
Sanofi and Regeneron’s next-gen immunology drug Dupixent is on fire. Already on its way to blockbusterland after grabbing a key asthma nod last October, the drug scored two back-to-back regulatory wins at the FDA.
Regeneron/Sanofi wins US approval for expanded use of skin drug expressbpd
March 13, 2019
The US Food and Drug Administration said it approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA’s eczema drug Dupixent to include patients aged between 12 and 17.
Sanofi, Regeneron's Dupixent gains expanded approval in US for certain adolescents with atopic dermatitis firstwordpharma
March 12, 2019
Sanofi and Regeneron Pharmaceuticals on Monday announced that the FDA has expanded approval of Dupixent (dupilumab) to include use in adolescents aged 12 to 17 years with moderate-to-severe atopic dermatitis that is not adequately controlled with topical
Sanofi/Regeneron’s Dupixent shows more promise in nasal polyps pharmaphorum
February 27, 2019
Sanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase 3 results in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Sanofi, buoyed by Dupixent and rare disease drugs, expects a brighter 2019 fiercepharma
February 24, 2019
Sanofi’s growth momentum seems to have returned after years of diabetes-related decline. With a major contribution from Dupixent—plus some help from new blood disorder treatments added through recent acquisitions and a renewed focus on oncology—Sanofi is
FDA approves Sanofi/Regeneron’s Dupixent in asthma pharmaphorum
December 21, 2018
The US regulator has approved Sanofi/Regeneron’s Dupixent (dupilumab) in a new asthma indication, a key step in the companies attempt to build a blockbuster franchise around the drug.
Four new medicines available via NHS Scotland pharmatimes
November 27, 2018
The Scottish Medicines Consortium has cleared funds for use of four new medicines by NHS Scotland, including Sanofi’s biologic Dupixent for dermatitis.

Previous page 1 2 3 4 5 Next page